The linkage of heterodimeric (α/β) integrin receptors with their extracellular matrix (ECM) ligands and intracellular actin cytoskeleton is a fundamental step for controlling cell adhesion and migration. Binding of the actin linking protein, talin, to integrin β cytoplasmic tails (CTs) induces high affinity ligand binding (integrin activation), whereas binding of another actin linking protein, filamin, to the integrin β CTs negatively regulates this process by blocking the talin-integrin interaction. Here we show structurally that migfilin, a novel cytoskeletal adaptor highly enriched in the integrin adhesion sites, strongly interacts with the same region in filamin where integrin β CTs bind. We further demonstrate that the migfilin interaction dissociates filamin from integrin and promotes the talin/integrin binding and integrin activation. Migfilin thus acts as a molecular switch to disconnect filamin from integrin for regulating integrin activation and dynamics of ECM-actin linkage.
Cells reside in a protein network, the extracellular matrix (ECM). Cell-ECM contact is crucial for many physiological and pathophysiological processes and is primarily mediated by heterodimeric (α/β) transmembrane receptors, the integrins (1). Integrins engage a variety of ECM proteins via their extracellular domains while connecting to actin cytoskeleton via their small cytoplasmic tails (CTs). The ability of integrins to bind to their ligands is uniquely controlled by the integrin CTs via a process called "inside-out signaling", i.e., upon cellular stimulation, an integrin, typically expressed in a latent state, can receive intracellular signal(s) at its CTs, which transmits through the transmembrane domain to the extracellular domain thereby converting the receptor from a low to a high affinity state (integrin activation). How such long range information transfer is initiated and regulated has been the central topic of integrin/cell adhesion research over the decades (For recent reviews, see [2] [3] [4] [5] . Structural/biochemical studies have indicated that the inside-out signaling involves the unclasping of the integrin α/β CT complex (6) (7) (8) (9) , followed by extensive rearrangement of transmembrane domain and extracellular domain (10) (11) (12) (13) . Talin, a large actin linking protein, was found to play a key role in the unclasping process by binding to the integrin β CTs (7) (8) 14) . Talin activity appears to be controlled by multiple factors or pathways (15) (16) (17) (18) (19) (20) .
Relevant to the present study is the role of filamin, another major actin crosslinking protein (21) (22) , in integrin activation. Filamin was found to share an overlapping binding site on integrin β CTs with talin and thus suppress the talinintegrin interaction (16) . Gene-silencing of filamin in various cell lines to remove the filamin-integrin connection enhances integrin activation (16, 23) , whereas increased filamin-integrin interaction inhibits cell migration (24) -a process critically dependent on integrin activation. Together these observations support the notion that filamin binding to integrin serves as a cellular brake to control the dynamics of the integrin activation by inhibiting talin function and ECM-cytoskeleton communication. The mechanism as to how the filamin brake is turned off to promote the integrin activation and cell migration is not understood.
Filamin is known to contain an Nterminal actin binding domain (ABD) and a long rod-like domain of 24
immunoglobulin-like repeats, of which repeat 21 (IgFLN21) was shown to play a key role in binding to integrin β CTs and blocking the talin/integrin β CT interaction (16) . Interestingly, IgFLN21 also recognizes another intracellular protein called migfilin, which has been shown to be an important regulator of integrin-mediated cytoskeletal rearrangements, cell shape change (25) , and cell migration (26) .
In an effort to dissect the complex intermolecular interactions between migfilin, filamin and integrin, we have undertaken a detailed structural/functional analysis. Using NMR spectroscopy, we have mapped the precise IgFLN21 binding region in migfilin, which is located at the extreme N-terminal (1-24) of migfilin (migfilin-N), and we solved solution structure of the IgFLN21/migfilin-N complex. To our surprise, despite little sequence homology, migfilin binds to the same region in IgFLN21 where integrin β CT binds. Detailed NMR and biochemical analyses demonstrate that the migfilin-filamin interaction is an order of magnitude higher affinity than the integrin-filamin interaction and that the migfilin binding to filamin can competitively dissociate filamin from integrin and thus promote the talin/integrin interaction. Using multiple functional approaches, we further show that migfilin, but not its filamin binding defective mutant, significantly enhances the integrin activation. These data suggest a novel regulatory pathway in which the binding of filamin to its downstream target migfilin switches off the integrin-filamin connection, thereby promoting the talin binding to and activation of integrins.
Experimental Procedures
Plasmid, peptide constructs and purification -Human IgFLNc21(2282-2395) was cloned into pGEX 5X-1 (Amersham) with glutathione Stransferase as fusion tag and expressed in E.coli BL21 (DE3). Cells were induced at room temperature with 250mM IPTG for 16 hours when A 600 was 0.6. The protein was purified on glutathione-sepharose 4B to homogeneity and cleaved with factor Xa to release the fusion partners. Rebinding of GST to the column gave a preparation consisting predominantly of IgFLNc21, which was then subjected to gel filtration to remove residual GST to yield homogeneous IgFLNc21. A five amino acid segment remains with IgFLNc21 as a cloning artifact bringing the total length of the fragment used for structure determinations to 119 residues. To prepare 15 N and/or 13 C-labeled protein, 15 NH 4 Cl and [
13 C] glucose were added to M9 medium. The N-terminal 85-residue filamin binding domain of migfilin (Migfilin-Nter) was cloned in pMalC2X vector and expressed in E. coli BL21 . The E. coli expressed MBP-MigfilinNter protein was used for initial binding studies to filamin and specific binding of migfilin to IgFLNc21 was confirmed by HSQC perturbation. Subsequent cleavage to release Migfilin-Nter was only partly successful as the protein tended to degrade on purification. GST fused Migfilin-Nter was therefore expressed along with chaperone coexpression (Takara) in E. coli to generate Migfilin-Nter of better quality and quantity. N-terminal migfilin peptides, 34 and 24 residues in length, and β7 peptide (see Fig 2A) were synthesized by the in-house Biotechnology Core facility. IgFLNa21 (2236-2329) was cloned in pGSTparallel vector, expressed in E. coli BL21 (DE3) and purified using standard protocols. GFP-tagged migfilin was generated using the pEGFP-N1 vector using the EcoRI and KpnI restriction sites. (27) and visualized PIPP (28) . PASA software was used in the assignment of chemical shifts (29) .
Isothermal Titration Calorimetry (ITC)
Structure Calculation -X-plor-NIH (30) was used for calculating structure. The structure of IgFLNc21 was calculated with intramolecular NOEs and dihedral angle restraints derived from the TALOS program (31). The complex structure was then calculated by including 130 intermolecular NOEs between IgFLNc21 and migfilin-N and intramolecular NOEs for migfilin-N.
Hydrogen-Deuterium exchange-based experimental hydrogen bonding constraints were also used for further refinement at the final stage of the structure calculations. Structure quality was evaluated using PROCHECK (32) . The final 20 lowest energy structure coordinates are deposited in the protein data bank (PDB) and is assigned as 2K9U. The complete list of constraints used for structure calculation is submitted to BMRB database (#16002).
Western blotting -Purified platelets from 50ml blood were lysed in 50mM Tris.HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100 and 1 tablet of protease inhibitor (Roche) by gentle pipetting. Lysed platelets were centrifuged at 13000g for 5 minutes and the supernatant was used for coimmunoprecipitation experiments. From this lysate, 100µl (2 mg protein) was diluted with 900µl RIPA buffer (1X Tris buffered saline, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.004% sodium azide) containing PMSF, protease inhibitor cocktail and sodium orthovanadate (Santa Cruz Biotechnology). The diluted lysate was precleared with protein A/G PLUS beads (Santa Cruz Biotechnology) for 45 minutes. The supernatant (1ml) was incubated with 25µl anti-filamin antibody (Cell Signaling Technology) with mild rocking for 4 hours, and 40µl protein A/G was added followed by overnight incubation.. Amount of integrin β3 bound to filamin was estimated in the presence/absence of migfilin-N peptide in the platelet lysate by western blotting using anti-integrin β3 antibody (BD Biosciences).
Isolation of platelets from human bloodPlatelets were isolated as previously described (33) . Briefly, blood was drawn from healthy volunteers into acid-citratedextrose (ACD: 65mM citric acid, 85 mM sodium citrate, 111 mM dextrose; pH 4.61) and 2 µM PGE 1. Blood was centrifuged to obtain platelet-rich-plasma (PRP) which was then further centrifuged and the platelet pellet, was suspended in Ca 2+ and Mg 2+ -free Tyrode's buffer (138mM NaCl, 12mM NaHCO 3 , 0.36mM Na 2 HPO 4 , 2.9 mM KCl, 10 mM HEPES, 0.1% glucose, 0.1% BSA, pH 7.4). This was filtered through a Sepharose CL-4B (GE Healthcare) column in Tyrodes' buffer to obtain the platelets preparations used. Platelet count was determined using an automated cell counter (Nexcelcom Bioscience). MgCl 2 and CaCl 2 in the concentrations of 1 mM and 2mM. respectively, were added to the platelet suspension just before experiments, unless otherwise indicated.
A5 cells -Chinese hamster ovary (CHO) cells stably expressing αIIbβ3 integrin (A5 cells) were detached as described (9).
Peptide conjugation -Truncated versions of IgFLN21 binding migfilin-N wild type and mutant peptides (K 4 PEKRVASSVFITLAP 19 C and K 4 PEKRVADSAFITLAP 19 C), were made with an additional C-terminal cysteine residue (in italic and bold). CR 7 transport peptide was activated with 2, 2' -dithiobis(5-nitropyridine) and conjugated to the migfilin peptides by minor modifications of reported methods (34) . The conjugated peptides were purified by HPLC and conjugation confirmed by electrospray ionization mass spectrometry. Conjugated peptides were also made with a single FITC-group at the Nterminus, adding the FITC group during the synthesis of the peptides.
Peptide uptake into platelets and A5 cellsPeptide uptake into platelets and A5 cells was analyzed by flow cytometry (FACS) and confocal microscopy. Gel-filtered platelets (5 X 10 8 mL -1 ) or A5 cells (1-2 X 10 6 mL -1 ) were incubated with 10 µM FITCWTmigfilinCCR7, FITC-MTmigfilinCCR7, FITC-migfilin, migfilin or CR7 peptides for 5 min at 37 o C and fixed with 0.5 % (platelets) or 2% (A5 cells) PFA in 1X PBS. Samples were washed and resuspended in PBS. All flow cytometry analyses were done in a BD LSR instrument (BD Biosciences), and data analyzed with FlowJo software 8.7.3 (Treestar). For each sample, 100,000 platelets or 10,000 A5 cells were counted. Platelets/A5 cells were prepared similarly for confocal microscopy. Cells were analyzed using a Leica microscope using a 100X oil immersion objective for platelets and 63X lens for A5 cells. αIIbβ3 activation in platelets. PAC1, the mAb which reacts selectively with the active conformation of αIIbβ3 was used as in (36) . Platelets (7-10 X 10 8 mL -) were incubated with 10 µM of the respective unlabeled peptides at 37 o C for 5 minutes followed by 40 µg mL -1 FITC-PAC1 IgM for 30 min at room temperature in dark. This was followed by addition of 500 µL of the Tyrodes' buffer (pH 7.4) and immediate analysis by FACS. Data acquisition and processing was same as for peptide uptake analyses. However, specific binding was expressed in terms of median fluorescent intensities (MdFI). Non-specific binding was based on binding due to FITC-PAC1 alone. At the end of each experiment, intensity calibration beads were run as above for fibronectin/HUTS4 binding of A7 cells. The Relative Fluorescent Intensities (RFI) displayed on graphs are the MdFI based on the calibration beads.
Fibronectin or HUTS-4 binding to A7 cells -

PAC1 or Fibrinogen binding of A5 cells -50 µl aliquots of A5 cells (1.5-2 X10
6 ml -1 ) were incubated with 10 µM of unlabeled peptides at 37 o C for 5 min and PAC1 binding done as described (9) Platelet aggregation -Effect of FITClabeled or unlabeled migfilin peptides on platelet aggregation was examined using an aggregometer (Chronolog Corp). In siliconized cuvettes, Tyrode's buffer supplemented with 2mM CaCl 2 and 1mM MgCl 2 and platelets (0.5-4 X 10 8 mL -1 ) were equilibrated at 37 o C for 5 minutes. Then, 10 µM of the selected peptide or agonist was added, and aggregation monitored for 5 min at 37 o C with stirring. The final volume in each cuvette was 500 µL. TRAP6 (10µM concentration) was used as a positive control, and baseline for 100% aggregation was set with Tyrode's buffe. Quantitation of the effects of the peptides is based by assigning TRAP6 aggregation a value of 100%.
RESULTS
Characterization of migfilin binding to filamin
Migfilin (25) , also known as Cal (37) or FBLP-1A (38) , is a widely expressed 373 amino acid protein containing an N-terminal region, a middle proline rich region, and three C-terminal consecutive LIM domains. Migfilin has two isoforms: migfilin(s) that lacks the proline-rich region, and FBLP-1 that lacks the third LIM domain (39) . Previous functional studies have shown that the N-terminal 1-85 of migfilin recognizes repeat 21 of Filamin A or C (isoforms of 91% identity, Figure S1 ) (25) . Migfilin 1-85 has no sequence homology to any known protein and its binding mode to filamin is unknown. Figure 1A shows the Figure 1B shows the converse HSQC spectrum, 15 Nlabeled migfilin 1-85 in the absence and presence of unlabeled IgFLNc21. The free form of migfilin 1-85 appears to be intrinsically unstructured as indicated by its very narrow spectral dispersion. However, upon binding to IgFLNc21, 12 residues in migfilin 1-85 underwent dramatic chemical shift changes whereas the majority of the signals remained unperturbed, indicating that only a small portion of migfilin is involved in binding to IgFLNc21, but this portion appears to be changed dramatically by the interaction. To map the precise filamin binding region in migfilin 1-85, we synthesized two deletion mutants, truncating the C-terminus of migfilin 1-85 to generate migfilin 1-36 and migfilin 1-24. Figure 1A shows that these deletion mutants induced identical chemical shift changes in IgFLN21 compared to migfilin 1-85, demonstrating that the first 24 residues of migfilin are sufficient for binding to IgFLNc21. This is consistent with the previous cell-based analysis in which deletion of migfilin 1-24 (migfilin-N) completely abolished the migfilin binding to filamin and impaired actin assembly (25) . During all the above HSQC titrations no appreciable increase in line widths was observed. Many residues that could not be assigned with the free form of filamin appeared sharper indicating better structuring of the repeat, thereby negating any appreciable dimer formation on migfilin binding. Filamin A repeat 21 (IgFLNa21) also interacted with migfilin-N in a similar manner (See supplementary Figure S2 ) with essentially the same affinity (Kd ~2.5µM) as IgFLNc21 (Kd ~2.4µM), as shown by isothermal titration calorimetry (ITC) experiments (Figure 2) . Interestingly, migfilin-N induced a quite distinct spectral pattern in IgFLN21 as compared to integrin β7 CT ( Figure S2) , which is the highest affinity integrin β CT binding partner of IgFLN21 (16) . Overall, more significant chemical shift changes of IgFLN21 occurred upon binding to migfilin-N than to β7 CT, suggesting that the filamin/migfilin interaction is stronger than the filamin/integrin interaction. To confirm this, we performed the ITC experiments, which revealed that the affinity of migfilin-N/IgFLNa21 was an order of magnitude higher affinity than that for integrin β7/IgFLNa21 (Figure 2 ).
NMR structure of IgFLN21 in complex with migfilin-N reveals that migfilin and integrin β CTs share an overlapping binding site on IgFLN21
Recent crystallographic data have resolved how IgFLNa21 and integrin β CTs interact (16) . However, sequence comparison between integrin β CTs and migfilin-N revealed that, while integrin β CTs are highly homologous to one another, they are quite dissimilar from migfilin-N (Figure 2A ) leaving it uncertain how migfilin-N would bind to IgFLNa21. We therefore set out to determine the solution structure of IgFLNc21 in complex with migfilin-N using a series of multidimensional heteronuclear NMR experiments. Figure 2B shows the backbone superposition of 20 lowest energy NMR structures of the complex with r.m.s.d of 0.3Å for the backbone and 0.7Å for all heavy atoms (see Table 1 for statistics). The overall fold of IgFLNc21 ( Figure 2C ) is similar to the previously reported Filamin Ig repeats, including IgFLNa17, IgFLNa21, IgFLNc23, and IgFLNc24 (16, (40) (41) (42) . The backbone r.m.s.d between our NMR structure IgFLNc21 and the crystal structure of IgFLNa21 (16) (Figure 2A) , migfilin-N binds to exactly the same groove between β strands C and D in IgFLN21 ( Figure 2C and 2D) where integrin β CTs bind ( Figure 2E) . A total of 12 residues, K7-A18, of migfilin-N are involved in binding to IgFLN21, whereas in integrin β7, there is a 13-amino acid stretch sandwiched by two prolines that define the binding pocket. Migfilin lacks the N-terminal proline and has a lysine in its place (Figure 2A ). Structural inspection revealed that migfilin-N forms a β-sheet with the strand C in IgFLNc21 ( Figure 2C ) via conserved backbone hydrogen bonds as also seen in the integrin β7/IgFLNa21 complex. However, the side chain interactions appear to be very different between the two complexes ( Figure 2F vs 2G). Substantial hydrophobic interactions involving V9xxxVFIxL17 of migfilin-N are observed in the migfilin-N/IgFLNc21 complex ( Figure 2G ). These hydrophobic residues are not conserved in integrin β CTs in which some of the corresponding positions are even occupied by hydrophilic residues (Figure 2A) . Hydrophobic residues L2327, I2329, V2331, I2339 and F2341 on IgFLNc21 surround the migfilin V13 and I15 side chains ( Figure 2G ), whereas the corresponding positions in β7 are I782 and hydrophilic T784, respectively ( Figure 2F ). F14 in migfilin-N also makes hydrophobic contact with IgFLN21 whereas the corresponding T783 in β7 is hydrophilic. Thus, while the conserved backbone hydrogen bond pattern provides a basis for how migfilin-N and integrin β CTs recognize the same groove in IgFLNc21, the significantly more hydrophobic interactions in the migfilin-N/IgFLNc21 complex may explain why migfilin binds much tighter to IgFLNa21 than integrin β CTs. Among integrin β CTs, β7 has the closest hydrophobic match (YxxxIxxxI) ( Figure   2A ) to migfilin-N, V9xxxVFIxL17, which may explain why integrin β7 is the tightest binder to IgFLN21 among integrin β CTs (16) . While this manuscript is being submitted (Oct., 3, 2008) , the crystal structure of IgFLNa21 in complex with migfilin-pro5-pro19 has been reported ( Sept  30, 2008, ref 43) . Surprisingly, two IgFLNa21 molecules (chain A and chain B) were found to bind to one migfilin molecule due to possible crystallization effects. While the backbone interactions were conserved in these two configurations, the side chain interactions were markedly different. Briefly, chain A interacted with the side chains of S11, V13, and I15 of migfilin whereas chain B interacted with those of S12, F14, and T16. Our NMR structure clearly shows the IgFLNc21:migfilin-N interact to form a 1:1 complex (based upon lack of increase in line widths) and the interface is very similar to the crystal structure of chain A/migfilin, thus resolving the uncertainty of the crystal structures. The chain B/migfilin structure is likely a crystallization artifact.
Migfilin-N triggers filamin/integrin dissociation, promoting talin/integrin interaction.
The findings that migfilin-N and integrin β CT bind to the same site on IgFLN21 suggest that migfilin competes with integrin β CTs for binding to filamin.
To experimentally test this hypothesis, we performed the NMR-based competition experiments. Figure 3A shows that while integrin β3 CT underwent significant chemical shift changes upon binding to IgFLNa21, no changes occurred when adding equivalent migfilin-N, demonstrating that the IgFLNa21 binding to integrin β3 CT was disrupted by the strong IgFLNa21/migfilin-N interaction. Similarly, migfilin-N, which has much higher affinity for IgFLN21, displaced integrin β7 CT from binding to IgFLN21 ( Figure S4 ). This is consistent with the competition experiment reported by Lad et al (43) . NMR data also revealed that while IgFLNa21 blocks the integrin β CT binding to talin-PTB ( Figure  3B ), consistent with previous coimmunoprecipitation data (16), migfilin-N can effectively remove the blocking effect of IgFLN21 and promote the talin/β CT interaction ( Figure 3B ).
Migfilin promotes integrin activation.
Since the inhibition on talin/integrin β CT interaction by filamin negatively regulates integrin activation (16), the forgoing in vitro results led us to hypothesize that the migfilin binding to filamin may positively regulate integrin activation by dissociating filamin from integrins. To functionally test this hypothesis, we first overexpressed migfilin in human melanoma, A7 cells (44) and examined binding of Alexa Fluor 647 labeled 120 kDa fibronectin fragment, a ligand for β1 integrins, by FACS (45, 46) . Western blots also confirmed the presence of the β1 subunit in these cells as previously reported (47) . Figure 5A shows that binding of the fibronectin fragment to A7 cells increased ~4-fold when the cells were transfected with vectors encoding for full length migfilin as opposed to vector alone. Furthermore, binding of HUTS-4, a monoclonal antibody that reacts selectively with activated β1 integrins (48), also increased dramatically, demonstrating that over-expression of full-length migfilin enhances activation of integrins in these cells. These data provide first line of functional evidence to support our model. Similar experiments were also attempted with the matched M2 melanoma cells, which lack filamin A (44). HUTS-4 binding to these cells transfected with either vector alone or with full-length migfilin was high suggesting high constitutive activation of the integrins in these cells.
To more definitively elucidate how the specific migfilin/filamin interaction regulates integrin activation, we explored a widely used model CHO cell line expressing integrin αIIbβ3 (A5 cells) and to platelets which express high levels of this integrin. Full length migfilin was expressed poorly in the CHO cells. Therefore, we chose an alternative approach and designed a celldeliverable peptide that contained only IgFLN21 binding sequence of migfilin conjugated to a hepta-Arg tag at the Cterminus via a disulfide bond (termed CCR7) (see Figure S4A ). Compared to the full length migfilin, this peptide, if effectively delivered to the cell, should only recognize filamin, which then would promote dissociation of filamin from integrin and talin-mediated integrin activation. The hepta-Arg tag (R7) has been shown to be an efficient tool for peptide delivery into cells (34) . The polyarginine tag by itself has minimal effects on cell function and morphology (49) . Once the peptide enters the cell, the tag is cleaved by the more reducing intracellular environment thus minimizing non-specific tag-protein interactions (34) . Accordingly, we synthesized a peptide corresponding to residues K4-P19 of migfilin with the CCR7 importer disulfide linked to its C-terminus (WT-migfilin-CCR7, see Fig S4A) and a mutant peptide (MT-migfilin-CCR7) in which two residues involved in filamin binding, Ser11 was replaced by Asp and Val13 was replaced by Ala. This MT migfilin peptide binds at least 12.5 times weaker to IgFLNa21 than the WT peptide as assessed by NMR titration. These CCR7 peptides with a single FITC at their Nterminus were incubated with platelets and A5 cells and their uptake was monitored by fluorescence microscopy. Figure S5 shows that both the WT and MT CCR7 peptides successfully entered platelets. Two patterns were observed and are represented in the micrographs in Fig S5: a punctate and a uniform flourescent pattern. Similar patterns have been described in the literature of cells in which modified peptides have been taken up by cells (50, 51) . Similar micrographs were also obtained with A5 cells stably expressing αIIbβ3 (not shown). We also found no uptake of the FITC tagged migfilin peptide into the cells.
We first examined the peptide effect on the αIIbβ3 activation in A5 cells by using the activation specific mAb PAC-1 as the first antibody and Alexa Fluor 633-labeled goat anti-mouse IgM as the second antibody to detect PAC-1 binding to the integrin as previously described (20, 52) . Using the second antibody alone as background, the untreated A5 cells exhibited little reaction with PAC-1, consistent with the αIIbβ3 being in an unactivated state on these cells (see Figure 5B) . The untagged migfilin peptide and the tag itself had no effect on αIIbβ3 activation. In contrast, WTmigfilin-CCR7 activated the integrin. The MT-migfilin-CCR7 also induced PAC-1 binding, but it was significantly (p<0.05) less potent than WT-migfilin-CCR7 ( Figure  5B ). Thus, consistent with our hypothesis, the peptide corresponding to the filamin binding region of migfilin activated αIIbβ3, and mutations which reduced its filamin binding capacity reduced integrin activation. The differential effects of the WT-and MTmigfilin peptides were maintained over a wide range of peptide concentrations ( Fig  S6) .
Next, we sought to determine the αIIbβ3 activating activity of the migfilin peptides in platelets, the major blood cell expressing endogenous αIIbβ3. The activities of the migfilin peptides in platelets were found to be similar to those observed in the A5 cells. Namely, WT-migfilin-CCR7 induced extensive αIIbβ3 activation ( Figure   5C ). At the concentration tested, it had ~50% of the activity of the positive control, the thrombin receptor activating peptide, TRAP. The MT-migfilin-CCR7 also induced αIIbβ3 activation, but it was significantly (p<0.05) less potent than WTmigifilin-CCR7. The control peptides, CR7 alone and the untagged migfilin peptide had minimal activity ( Figure 5C ).
Further evidence for the functional activity of the WT-migfilin-CCR7 was obtained in platelet aggregation studies. As shown in Figure 6A , addition of WTmigfilin-CCR7 to a washed platelet suspension induced significant aggregation of the cells, a response critically dependent upon the αIIbβ3 activation. This effect was minimal at the same concentration of the MT-migfilin-CCR7, and was not observed at all with the tag alone or the untagged WTmigfilin peptide (see Figure 6A ). These differential effects of the WT and MT CR7 peptides on platelet aggregation were reproducible. Results shown in FigS7 are from three separate platelet preparations and are representative of data obtained with more than 10 different platelet preparations from at least 5 different donors. Peptides with or without the FITC label showed similar patterns of differential activities in platelet aggregation assays although the CR7 with FITC tended to give a higher background aggregation than non-FITC labeled CR7. In control experiments, we found that the ADP degrading enzyme, apyrase, at a concentration sufficient to block aggregation induced by 50 µM ADP, did not inhibit platelet aggregation induced by WT-migfilin-CCR7 (not shown). This latter result indicates that the effects of the peptides do not depend on the release of the agonist (ADP) either by induction of secretion or by lysis of some platelets.
To investigate if WT-migfilin-CCR7 peptide perturbed the filamin/integrin interaction in platelets, as predicted from our forgoing structural analyses, we performed co-immunoprecipitation experiments. Lysates from resting platelets were incubated with an antibody against filamin A, and coprecipitation of integrin β3 was detected by Western blotting with a mAb against the β3 subunit. Figure 6B shows that while filamin A specifically associates with integrin β3 in platelets, consistent with previous biochemical analysis (53), this association was significantly reduced upon adding migfilin-N. As a control, similar amounts of filamin A were immunoprecitated in the presence and absence of WT-migfilin-CCR7 ( Figure 6B , lower panel). Based on densitometric scans of these gels, the amount of β 3 immunoprecitated in the presence of the WT-migfilin peptide was lowered by 55±3 % compared with the control (n=4). These functional results thus strongly support the structure-based hypothesis that the binding of migfilin-N to filamin promotes integrin activation by dissociating the negative regulator filamin from integrins.
Discussion:
Dynamic regulation of integrin activation is important in many physiological cell adhesive events, including spreading, migration, and survival, and also influences pathological responses, such as tumor metastasis. Despite recent advances in unraveling the essential role of talin in activating integrins, the regulatory factor(s)/pathway(s) that control the activation process remain poorly defined. The extensive structural and functional data we have obtained here now suggest that migfilin binding to filamin provides at least one such regulatory pathway. Our evidence for involvement of this pathway have been obtained at both structural and functional levels: (1) Structurally, we showed that the N-terminal fragment of migfilin (migfilin-N) specifically binds to a region in filamin where integrin β CTs also binds and that such binding dissociates filamin from integrin and promotes the talin/integrin interaction. The structural data strongly suggest that migfilin-N may act as an offswitch for the filamin/integrin interaction that prevents talin binding and integrin activation. (2) Functionally, we showed: (i)) overexpression of migfilin significantly enhanced the integrin activation ~2-4 fold in A7 cells; (ii) cell delivery of migfilin-N, induced activation of a prototypic integrin αIIbβ3 in both a model cell system, A5 cells, and in a naturally-occurring cell, platelets; (iii) migfilin-N induced platelet aggregation, an event critically dependent upon the αIIbβ3 activation. In the peptidebased functional assays, a mutant migfilin peptide that has decreased affinity for filamin was substantially less effective in integrin activation. The decrease but not complete loss in the filamin binding activity of this migfilin mutant is consistent with its retention of some filamin binding activity ( Figure S4B ). The nature of cell permeable peptide uptake and resultant biological activities is yet to be resolved in the scientific literature (54) .
How is migfilin localized to integrin adhesion sites to confer its regulatory function? Recent studies have identified a cytoskeletal protein kindlin-2/mig-2 that can efficiently recruit migfilin to cell-ECM adhesion sites (25) . Kindlin-2 belongs to a family of kindlin proteins (kindlin-1, 2, 3) that are highly homologous and contain talin-like FERM domains. Remarkably, both kindlin-2 and kindlin-3 have been shown to be also involved in regulating talin-mediated integrin activation (19) (20) (55) (56) . Kindlin-2 and talin were shown to bind to different regions of membrane-distal β 3 CT and act synergistically in inducing integrin activation (20, 56) . The kindlin-2 function has been shown to be dependent upon its interaction with migfilin as deletion of N-terminal kindlin-2 critical for binding to migfilin (25) abolished the kindlin-2 effect on integrin activation (20) and dramatically impaired localization of migfilin to integrin containing focal adhesion sites and cell spreading (25) . Thus, filamin, migfilin, and kindlin(s) may constitute a unit within the multi-protein machinery for cooperative regulation of integrin activation. Accordingly, migfilin may play a dual role in this pathway ( Figure 7 ): (i) binding filamin via its N-terminus, to promote the dissociation of inhibitory filamin from integrins thereby facilitating the talin/integrin interaction. (ii) binding kindlin-2 or 3 via its C-terminal LIM domain (25) to promote the anchoring of kindlin-2/3 to integrin β3 CT and to further strengthen the talin effect as a co-factor for integrin activation. It should be noted that since, filamin is a major actin crosslinking protein and is critical for maintaining the actin network, the migfilin-induced disconnection between integrin and filamin not only facilitates the talin-mediated integrin activation but also may cause temporal rearrangement of the integrin-actin linkage to facilitate the cytoskeleton remodeling. This model is supported by previous unexplained functional data which showed that specific disruption of filamin/migfilin interaction by deleting migfilin-N impaired actin assembly (25) . These facts apart, migfilin is not an evolutionarily conserved protein in multicellular animals being absent in Drosophila. It is therefore possible that migfilin and migfilin(s) modulation of integrin activity is superimposed on a more fundamental activation cascade. Cell type and cellular metabolic status may determine the outcome of interventions like over expression and protein uptake studies.
In summary, we have identified a novel migfilin/filamin-mediated pathway for regulating integrin activation. Our combined structural and functional data provide compelling evidence that the binding of migfilin to filamin disconnects the inhibitory filamin from integrins thereby promoting the efficient talin binding to and activation of the receptors and the reorganization of the actin cytoskeleton. In light of the central importance of the talin and its role in integrin activation in various pathological processes, our findings, especially the celldelivery peptides, may lead to the design of better compounds to repair dysfunction of integrin-mediated adhesive processes. These peptides may also provide valuable means to examine integrin signaling and cell adhesion in diverse biological processes. (25) . The recruited migfilin promotes dissociation of filamin from integrins, which is bound to the resting integrin and inhibits the talin/integrin interaction (16) as well as
